Edwards Lifesciences (Edwards Lifesciences) Long-Term Capital Lease Obligation

: $73 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Edwards Lifesciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $73 Mil.

Edwards Lifesciences's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($64 Mil) to Sep. 2023 ($70 Mil) and increased from Sep. 2023 ($70 Mil) to Dec. 2023 ($73 Mil).

Edwards Lifesciences's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($69 Mil) to Dec. 2022 ($70 Mil) and increased from Dec. 2022 ($70 Mil) to Dec. 2023 ($73 Mil).

Edwards Lifesciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Edwards Lifesciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

58.90

72.70

69.10

69.50

73.00

Edwards Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																69.50	66.20	63.50	70.00	73.00

Edwards Lifesciences (NYSE:EW) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Edwards Lifesciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Edwards Lifesciences (Edwards Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

EW:Mexico 1EW:Italy EWL:Germany EWL:Germany EWL:Germany E1WL34:Brazil EWLS:Austria

Address

One Edwards Way, Irvine, CA, USA, 92614

Website

https://www.edwards.com

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Executives

Bobo Donald E Jr	officer: CVP,Strategy/Corp Development	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem	director, officer: Chairman & CEO	C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem	officer: CVP, CFO	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra	officer: CVP, Surgical Structural Heart	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood	officer: CVP, THV Replacement	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman	officer: CVP, Critical Care	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz	officer: GM & SVP, Surgical	ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone	director	C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier	officer: CVP, EMEA, Canada, Latin Amer	C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a.	officer: VP, Corp. Controller (Principa	ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian	officer: CVP, Surgical Heart Valves	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang	officer: CVP, Japan & Intercontinental	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh	director	9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614